BRISTOL MYERS SQUIBB CO

Listed Company

BMYCIK 0000014272NYSELarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$48.19B

Net Income

$7.05B

Total Assets

$90.04B

Equity

$18.47B

Shares Out

2.04B

Op. Cash Flow

$14.16B

Business

Bristol Myers Squibb Co. operates as a global biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of prescription medicines. It offers a portfolio of small molecules, biologics, ADCs, CAR‑T cell therapies and radiopharmaceuticals across oncology, hematology, immunology, cardiovascular, neuroscience and related areas. The company reports a single business segment that manages R&D platforms, a growth and legacy product portfolio, and alliances for co‑development and commercialization. Its products are sold worldwide primarily to wholesalers, distributors and specialty pharmacies, and distributed to retailers, hospitals, clinics and government agencies.

Summary from filing dated 2025-02-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total Revenues	48,194	48,300	45,006	46,159	46,385
Cost of products sold	13,936	13,968	10,693	10,137	9,940
Selling, general and administrative	7,267	8,414	7,772	7,814	7,690
Research and development	9,951	11,159	9,299	9,509	10,195
Acquired IPRD	3,721	13,373	913	815	1,159
Amortization of acquired intangible assets	3,317	8,872	9,047	9,595	10,023
Other (income)/expense, net	674	893	−1,158	576	−720
Total Expenses	38,866	56,679	36,566	38,446	38,287
Earnings/(Loss) before income taxes	9,328	−8,379	8,440	7,713	8,098
Income tax provision	2,272	554	400	1,368	1,084
Net earnings/(loss)	7,055	−8,933	8,040	6,345	7,014
Noncontrolling Interest	2	15	15	18	20
Net earnings/(loss) attributable to BMS	7,054	−8,948	8,025	6,327	6,994
Basic (in dollars per share)	3.47	−4.41	3.88	2.97	3.15
Diluted (in dollars per share)	3.46	−4.41	3.86	2.95	3.12

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	10,209	10,346	11,464	9,123	13,979
Marketable debt securities	464	513	816	130	—
Receivables	11,414	10,747	10,921	9,886	9,369
Inventories	2,690	2,557	2,662	2,339	2,095
Other current assets	4,613	5,617	5,907	5,795	4,832
Total Current assets	29,390	29,780	31,770	27,273	33,262
Property, plant and equipment	7,543	7,136	6,646	6,255	6,049
Goodwill	21,754	21,719	21,169	21,149	20,502
Other intangible assets	19,103	23,307	27,072	35,859	42,527
Deferred income taxes	5,378	4,236	2,768	1,344	1,439
Marketable debt securities	396	320	364	0	—
Other non-current assets	6,474	6,105	5,370	4,940	5,535
Total Assets	90,038	92,603	95,159	96,820	109,314
Short-term debt obligations	2,261	2,046	3,119	4,264	4,948
Accounts payable	3,575	3,602	3,259	3,040	2,949
Other current liabilities	17,581	18,126	15,884	14,586	13,971
Total Current liabilities	23,417	23,774	22,262	21,890	21,868
Deferred income taxes	222	369	338	2,166	4,501
Long-term debt	42,850	47,603	36,653	35,056	39,605
Other non-current liabilities	5,043	4,469	6,421	6,590	7,334
Total Liabilities	71,533	76,215	65,674	65,702	73,308
Commitments and Contingencies (Note 20)	—	—	—	—	—
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 2,510 in 2025 and 2,868 in 2024, liquidation value of $50 per share	0	0	0	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2025 and 2024	292	292	292	292	—
Capital in excess of par value of stock	46,387	46,024	45,684	45,165	44,361
Accumulated other comprehensive loss	−1,524	−1,238	−1,546	−1,281	−1,268
Retained earnings	16,896	14,912	28,766	25,503	23,820
Less cost of treasury stock 887 million common shares in 2025 and 894 million common shares in 2024	−43,579	−43,655	−43,766	−38,618	−31,259
Total BMS Shareholders Equity	18,473	16,335	29,430	31,061	35,946
Noncontrolling interest	33	53	55	57	60
Total Equity	18,506	16,388	29,485	31,118	36,006
Total Liabilities and Equity	90,038	92,603	95,159	96,820	109,314
Preferred stock, shares outstanding (in shares)	2,510	2,868	2,953	2,991	3,484
Preferred stock, shares issued (in shares)	2,510	2,868	2,953	2,991	3,484

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization, net	4,011	9,600	9,760	10,276	10,686
Deferred income taxes	−965	−2,089	−3,288	−2,738	−1,393
Stock-based compensation	553	507	518	457	583
Impairment charges	1,098	2,963	255	179	1,207
Divestiture gains and royalties	−1,165	−1,119	−884	−1,063	−684
Equity investment (gains)/losses, net	−280	−16	160	801	−745
Contingent consideration fair value adjustments	351	0	0	−9	−542
Other adjustments	232	94	300	223	183
Receivables	−295	264	−995	−663	−1,054
Inventories	−184	−486	−751	−69	13
Accounts payable	−2	184	198	109	245
Rebates and discounts	−441	1,484	904	427	863
Income taxes payable	−4	−1,260	−603	−1,423	−1,063
Other	471	624	−667	−610	−265
Net cash provided by operating activities	14,156	15,190	13,860	13,066	16,207
Sale and maturities of marketable debt securities	1,975	1,122	733	6,411	4,196
Purchase of marketable debt securities	−2,000	−769	−1,774	−3,592	−5,478
Proceeds from sales of equity investments	77	265	215	218	2,579
Capital expenditures	−1,311	−1,248	−1,209	−1,118	−973
Divestiture and other proceeds	1,071	1,099	909	1,305	748
Acquisition and other payments, net of cash acquired	−3,944	−21,821	−1,169	−4,286	−1,610
Net cash provided by/(used in) investing activities	−4,132	−21,352	−2,295	−1,062	−538
Proceeds from issuance of short-term debt obligations	0	3,000	0	0	—
Repayments of short-term debt obligations	0	−3,000	0	0	—
Other short-term financing obligations, net	25	99	−120	194	—
Proceeds from issuance of long-term debt	5,740	12,883	4,455	5,926	0
Repayments of long-term debt	−10,940	−2,873	−3,879	−11,431	−6,022
Repurchase of common stock	0	0	−5,155	−8,001	−6,287
Dividends	−5,045	−4,863	−4,744	−4,634	−4,396
Stock option proceeds and other, net	−128	−106	27	984	—
Net cash provided by/(used in) financing activities	−10,348	5,127	−9,416	−16,962	−16,224
Effect of exchange rates on cash, cash equivalents and restricted cash	195	−137	45	−33	−102
Increase/(decrease) in cash, cash equivalents and restricted cash	−129	−1,172	2,194	−4,991	−657

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro